Head-to-Head Study Confirms Plasma p-Tau231 Rises First in Early AD
Plasma p-tau217 and p-tau181 better track amyloid PET, tangles, and subtle cognitive decline.
ALL NEWS
611 RESULTS
Sort By:
- Most Recent
- Most Commented
Blood Tests: Charting the Path to Primary Care
Certain blood biomarker tests can tell that amyloid has built up in a person's brain and that their thinking will decline. What are the challenges ahead before these tests can be rolled out to medical care settings everywhere?
Blood Tests Go Head-to-Head in Community Cohorts
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
Alzheimer's Blood Tests Have Arrived; Road to Broad Use Still Stretches On
Finally, blood biomarkers for AD are here. Alas, the path to routine use is fraught. At AAIC, scientists discussed new guidelines, head-to-head comparisons, and logistical, technical, and ethical hurdles ahead.
Crenezumab Secondaries Negative; Gantenerumab OLE Hints at Efficacy
At AAIC, secondary endpoint data from the API Colombian study showed trends favoring crenezumab, while people taking gantenerumab in open-label extensions declined more slowly than matched controls.
In Down's Syndrome, Blood P-Tau217 Detects Plaques and Tangles
In young adults with Down’s, plasma phospho-tau217 correlated with amyloid and tau PET positivity. With great accuracy.
Digital Tools Abound, Yet Remote Biomarkers for FTD Remain Exploratory
At the Holloway Summit, scientists, regulatory, and foundation leaders discussed how to advance digital biomarkers from the idea stage into standardized, reliable tools for diagnosis and trials.
Digital Biomarkers of FTD: How to Move from Tech Tinkering to Trials?
The inaugural Holloway Summit, hosted by AFTD, focused on the development of digital health technologies to track the progression of FTD’s myriad manifestations.
Aggregates of TDP-43 in Muscle—Potential ALS Marker?
TDP-43 inclusions in intramuscular nerve bundles, paired with clinical criteria, may enable diagnoses at early stages of ALS.
Does TSPO PET Measure Microglia Activation or Density?
A provocative new study suggests that unlike in mice, TSPO in people does not rise with microglial activation; instead, a higher PET signal reflects more microglia.
FDA Approves Fujirebio’s CSF Test for AD—Quest Diagnostic Offers Plasma Test
The first FDA approval of a CSF test, and increased options for plasma testing, will give patients easier access to these diagnostic aids. Will physicians interpret them properly?
Tau-PET Imaging Brings Braak Staging to Life
Using a sensitive tau-PET tracer, researchers tied neuroimaging, CSF biomarkers, and cognitive symptoms to the progression of tau pathology in AD.
Diversity: FDA Guidance and New Data on Incidence/Biomarkers by Race
The guidance may help sponsors increase racial diversity in clinical trials. Studies in U.S. veterans and other cohorts show differences in incidence, and in blood levels of tau by race.
Ratio of Short to Long Aβ Peptides: Better Handle on Alzheimer's than Aβ42/40?
Low levels of Aβ37, 38, 40 reflect low processive activity of γ-secretase. They track with age at onset in people with autosomal-dominant mutations, and may track with cognitive decline in sporadic AD.
Scientists Re-Analyze Aduhelm Data, Try to Parse Who Benefits
At AD/PD, some speakers sought to bolster the argument that amyloid removal slows cognitive decline, while others identified what type of patient is most likely to benefit.
Current Filters
- Biomarkers x